Abstract
Aims
The impact of glycemic optimization on lipoprotein subfraction parameters in apparently
normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined.
Methods
We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects
at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR
spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal
glycemic control (HbA1c ≤ 7.0%).
Results
Advanced lipoprotein analysis revealed a significant reduction from baseline in serum
concentrations of triglycerides (TG), cholesterol (C), and apolipoprotein (Apo)B-containing
lipoproteins of treated subjects (VLDL-TG: −21%, IDL-TG: −30%, LDL-TG: −34%, LDL-TG:
−36%, P < 0.05; VLDL-C: –23%, IDL-C: −44%, LDL-C: −16%; p < 0.05). Decreased VLDL and LDL lipids were mainly attributed to concomitant reductions
in the concentration of medium-sized VLDL (–36%) and medium-sized LDL (–31%) and,
to a lesser extent, to large-sized LDL (–14%). Notably, proatherogenic IDL characteristics
and related surrogates of atherogenicity were resolved upon achievement of optimal
glycemic status. Moreover, the concentration of HDL-TG was also reduced (−18%) at
follow-up.
Conclusions
Our data showed that the achievement of optimal glycemic control after T1D onset corrected
hidden derangements in ApoB-containing lipoproteins (particularly IDL) and HDL-TG
that are related to higher cardiovascular risk in poorly controlled T1D.
Keywords
Abbreviations:
ApoB (apolipoprotein B), ApoA-I (apolipoprotein A-I), Lp(a) (Lipoprotein (a)), 1H NMR (nuclear magnetic resonance), CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), CVD (cardiovascular disease), IDL (intermediate-density lipoprotein), LDL-C (low-density lipoprotein cholesterol), HDL-C (high-density lipoprotein cholesterol), NEFA (non-esterified fatty acids), T1D (type 1 diabetes mellitus), TG (triglycerides), VLDL (very-low-density lipoprotein)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dyslipidemia in Type 1 Diabetes: AMaskedDanger.Trends Endocrinol Metab. 2020; 31: 422-434
- Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia.Diabetes Res Clin Pract. 2021; 171: 108548https://doi.org/10.1016/j.diabres.2020.108548
- Cardiovascular Risk in Type 1 Diabetes Mellitus.Diabetes Ther. 2019; 10: 773-789
- Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.N Engl J Med. 2005; 353: 2643-2653
- Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.Curr Cardiol Rep. 2016; 18: 29
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.Lancet. 2009; 373: 1765-1772
- The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study.Diabetologia. 2017; 60: 2084-2091
- Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2020; 43: 1617-1635
- Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy.PLoS ONE. 2015; 10: e0136348https://doi.org/10.1371/journal.pone.0136348
- Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction.Eur Heart J. 2021; https://doi.org/10.1093/eurheartj/ehab293
- Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.Diabetes Metab Res Rev. 1999; 15: 412-426
- A new equation to estimate glomerular filtration rate.Ann Intern Med. 2009; 150: 604-612https://doi.org/10.7326/0003-4819-150-9-200905050-00006
- The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006; 6https://doi.org/10.1186/1471-230X-6-33
- Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy.J Lipid Res. 2015; 56: 737-746
- Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy.Anal Bioanal Chem. 2012; 402: 2407-2415
- Specific Nuclear Magnetic Resonance Lipoprotein Subclass Profiles and Central Arterial Stiffness in Type 1 Diabetes Mellitus: A Case Control Study.J Clin Med. 2019; 8: 1875https://doi.org/10.3390/jcm8111875
- Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience.Diabetes Care. 1992; 15: 886-894
- Quantitative relationship between plasma lipids and glycohemoglobin in type I patients. Longitudinal study of 212 patients.Diabetes Care. 1989; 12: 332-336
- Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus.Diabetes. 1992; 41: 12-17
- Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.Cardiovasc Diabetol. 2020; 19: 126https://doi.org/10.1186/s12933-020-01099-0
- Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus.Arterioscler Thromb. 1994; 14: 1933-1939
- Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.Diabetes. 1998; 47: 779-787
- Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes.Diabetes. 2002; 51: 1949-1956
- The role of triglycerides in atherosclerosis.Curr Cardiol Rep. 2011; 13: 544-552
- Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition.Atherosclerosis. 1991; 89: 49-57
- Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients.J Am Soc Nephrol. 1998; 9: 1277-1284
- LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study.Int J Cardiol. 2018; 264: 172-178
- Triacylglycerol accumulation and secretion in hepatocyte cultures. Effects of insulin, albumin and Triton WR 1339.Biochem J. 1992; 285: 655-660
- The release of hepatic triglyceride lipase from rat monolayered hepatocytes in primary culture.Endocrinol Jpn. 1990; 37: 437-442
- The effects of streptozotocin diabetes on hepatic triglyceride lipase activity in the rat.Metabolism. 1979; 28: 30-40
- The effects of fasting and streptozotocin diabetes on hepatic triglyceride lipase activity in the rat.Diabetes. 1977; 26: 58-60
- Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity.Diabetes Care. 1994; 17: 6-12
- Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes.Diabetes. 2002; 51: 3300-3305
- Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification.Diabetes. 2001; 50: 652-659
- Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein.J Lipid Res. 1998; 39: 613-622
- Phospholipid transfer protein activity and incident type 2 diabetes mellitus.Clin Chim Acta. 2015; 439: 38-41
- Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity.J Intern Med. 2012; 271: 490-498
- Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects.Atherosclerosis. 2011; 217: 253-259
- Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients.Diabetes. 1999; 48: 1631-1637
Article info
Publication history
Published online: November 12, 2021
Accepted:
November 8,
2021
Received in revised form:
October 27,
2021
Received:
July 11,
2021
Identification
Copyright
© 2021 Elsevier B.V. All rights reserved.
